Feature | June 02, 2014

St. Jude Medical Completes Acquisition of CardioMEMS

June 2, 2014 — St. Jude Medical announced the completion of its acquisition of the privately held CardioMEMS Inc., developer of the CardioMEMS heart failure (HF) management system. The acquisition was completed on May 30, 2014.

“St. Jude Medical’s acquisition of CardioMEMS shows our commitment to providing innovative medical device solutions that reduce the burden of complex diseases like heart failure, both on patients and healthcare systems. The CardioMEMS HF system achieves this goal by setting a new treatment paradigm for heart failure that reduces hospitalizations and improves the quality of life for patients,” said Daniel J. Starks, chairman, president and CEO of St. Jude Medical.

The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions when used by physicians to manage heart failure. St. Jude Medical will now begin its strategic launch of the CardioMEMS HF system in the United States.

The CardioMEMS HF system allows clinicians to stabilize pulmonary artery pressures by proactively managing medications and other treatment options while also providing an early indication of worsening heart failure, thereby improving heart failure patients’ quality of life, and reducing economic risks for hospitals and payers.

Bank of America Merrill Lynch acted as financial advisor and Gibson, Dunn & Crutcher LLP as legal counsel to St. Jude Medical. J.P. Morgan Securities LLC acted as financial advisor to CardioMEMS and Cooley LLP as legal counsel.

For more information: www.sjm.com

Related Content

News | Wearable Sensors| October 13, 2016
Biotricity Inc. announced recently that it will be expanding its existing research partnership with the University of...
News | Renal Denervation| October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...
Heartware HVAD, ventricular assist device, artificial heart, Medtronic
News | October 05, 2016
October 5, 2016 — Medtronic said two previously communicated global voluntary recalls related to the HeartWare Intern
CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
Sponsored Content | Videos | Heart Failure| September 02, 2016
The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by res
Respicardia, Remede, pacemaker for sleep apnea, central sleep apnea treatment

The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with central sleep apnea.

News | Heart Failure| September 02, 2016
September 2, 2016 — Results from an international, randomized study show that an implanted nerve stimulator significa
Overlay Init